Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer
Objective: Baseline bone health in postmenopausal women is poorly characterized in prospective series of early breast cancer (EBC) patients candidates to aromatase inhibitor (AI) therapy. Our objective is to comprehensively evaluate bone health in a prospective clinical cohort of patients recruited...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826275874307047424 |
|---|---|
| author | Servitja, S Nogués, X Prieto-Alhambra, D Martínez-García, M Garrigós, L Peña, M de Ramon, M Díez-Pérez, A Albanell, J Tusquets, I |
| author_facet | Servitja, S Nogués, X Prieto-Alhambra, D Martínez-García, M Garrigós, L Peña, M de Ramon, M Díez-Pérez, A Albanell, J Tusquets, I |
| author_sort | Servitja, S |
| collection | OXFORD |
| description | Objective: Baseline bone health in postmenopausal women is poorly characterized in prospective series of early breast cancer (EBC) patients candidates to aromatase inhibitor (AI) therapy. Our objective is to comprehensively evaluate bone health in a prospective clinical cohort of patients recruited prior to adjuvant AI therapy, with the aim of establishing potential AI impact on bone loss and fractures. Methods: From January 2006 to April 2010, we consecutively included 343 women with EBC who were about to start adjuvant AI therapy. Participants were assessed at baseline (before AI initiation) and at 3 months, with annual assessments thereafter. Bone mineral density (BMD), spine X-ray, bone metabolism (vitamin D [25(OH)D], bone turnover markers [BTM]), arthralgia and quality of life are measured. Results: Mean age was 61.9 years; 197 (57.4%) had been previously treated with tamoxifen; 145 (42.3%) were taking exemestane, 187 (54.5%) letrozole, and 11 (3.2%) anastrozole. Analysis of baseline data shows only 59 women (17.7%) had normal BMD; 200 (60.1%) had osteopenia and 74 (22.2%) had osteoporosis; 39 women (11.4%) had a prevalent fracture, 293 (89.1%) had 25(OH)D insufficiency (<30ng/ml), and 61 (18.5%) severe deficiency (<10ng/ml). Low 25(OH)D concentrations were associated with lower BMD and 233 (67.9%) participants had some degree of arthralgia. Conclusions: Low bone mass, prevalent fractures and vitamin D insufficiency were highly prevalent among candidates to adjuvant AI for EBC. Therefore, it is crucial to assess BMD, prevalent fractures and 25(OH)D concentrations before starting AI therapy and during follow-up. © 2011 Elsevier Ltd. |
| first_indexed | 2024-03-06T23:05:27Z |
| format | Journal article |
| id | oxford-uuid:639ec37e-4cf0-44a1-b394-41b5800b952f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:05:27Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:639ec37e-4cf0-44a1-b394-41b5800b952f2022-03-26T18:14:09ZBone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:639ec37e-4cf0-44a1-b394-41b5800b952fEnglishSymplectic Elements at Oxford2012Servitja, SNogués, XPrieto-Alhambra, DMartínez-García, MGarrigós, LPeña, Mde Ramon, MDíez-Pérez, AAlbanell, JTusquets, IObjective: Baseline bone health in postmenopausal women is poorly characterized in prospective series of early breast cancer (EBC) patients candidates to aromatase inhibitor (AI) therapy. Our objective is to comprehensively evaluate bone health in a prospective clinical cohort of patients recruited prior to adjuvant AI therapy, with the aim of establishing potential AI impact on bone loss and fractures. Methods: From January 2006 to April 2010, we consecutively included 343 women with EBC who were about to start adjuvant AI therapy. Participants were assessed at baseline (before AI initiation) and at 3 months, with annual assessments thereafter. Bone mineral density (BMD), spine X-ray, bone metabolism (vitamin D [25(OH)D], bone turnover markers [BTM]), arthralgia and quality of life are measured. Results: Mean age was 61.9 years; 197 (57.4%) had been previously treated with tamoxifen; 145 (42.3%) were taking exemestane, 187 (54.5%) letrozole, and 11 (3.2%) anastrozole. Analysis of baseline data shows only 59 women (17.7%) had normal BMD; 200 (60.1%) had osteopenia and 74 (22.2%) had osteoporosis; 39 women (11.4%) had a prevalent fracture, 293 (89.1%) had 25(OH)D insufficiency (<30ng/ml), and 61 (18.5%) severe deficiency (<10ng/ml). Low 25(OH)D concentrations were associated with lower BMD and 233 (67.9%) participants had some degree of arthralgia. Conclusions: Low bone mass, prevalent fractures and vitamin D insufficiency were highly prevalent among candidates to adjuvant AI for EBC. Therefore, it is crucial to assess BMD, prevalent fractures and 25(OH)D concentrations before starting AI therapy and during follow-up. © 2011 Elsevier Ltd. |
| spellingShingle | Servitja, S Nogués, X Prieto-Alhambra, D Martínez-García, M Garrigós, L Peña, M de Ramon, M Díez-Pérez, A Albanell, J Tusquets, I Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer |
| title | Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer |
| title_full | Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer |
| title_fullStr | Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer |
| title_full_unstemmed | Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer |
| title_short | Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer |
| title_sort | bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer |
| work_keys_str_mv | AT servitjas bonehealthinaprospectivecohortofpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT noguesx bonehealthinaprospectivecohortofpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT prietoalhambrad bonehealthinaprospectivecohortofpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT martinezgarciam bonehealthinaprospectivecohortofpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT garrigosl bonehealthinaprospectivecohortofpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT penam bonehealthinaprospectivecohortofpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT deramonm bonehealthinaprospectivecohortofpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT diezpereza bonehealthinaprospectivecohortofpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT albanellj bonehealthinaprospectivecohortofpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer AT tusquetsi bonehealthinaprospectivecohortofpostmenopausalwomenreceivingaromataseinhibitorsforearlybreastcancer |